ClinicalTrials.Veeva

Menu

Methadone Anesthesia For Kidney Transplant Receptors

U

University of Sao Paulo General Hospital

Status and phase

Unknown
Phase 3

Conditions

Surgery
Renal Failure Chronic

Treatments

Drug: Methadone
Drug: Fentanyl

Study type

Interventional

Funder types

Other

Identifiers

NCT04908345
MEFERENAL

Details and patient eligibility

About

Intraoperative methadone or fentanyl will be administered to patients submitted to kidney transplant surgery. Postoperative pain, analgesic consumption and side effects will be evaluated

Full description

Despite recent developments in postoperative pain control, many patients still experience moderate or severe pain after surgery. It is estimated that severe postoperative pain occurs in 20 to 40% of surgical procedures. With the development of kidney transplant services, a better study of the intraoperative analgesia used in this procedure and its impact on the postoperative is necessary. The management of postoperative pain in renal transplant recipients is essential to improve the quality of postoperative care, and may even impact the prognosis of the renal graft. One of the strategies to improve pain control in the perioperative period is the intraoperative use of intravenous methadone, given its pharmacokinetic profile. Methadone is an opioid agonist of µ receptors, it is also a Glutamate antagonist by blocking the N-methyl-D-aspartate (NMDA) receptor, and inhibits the reuptake of serotonin and norepinephrine. When administered in doses of 20 to 30mg, the analgesia generated by methadone can last from 24 to 36 hours. There is also evidence that the use of methadone in doses of 0.2 to 0.3 mg / kg is not associated with a higher incidence of side effects when compared to other opioids with short or intermediate duration of action, such as fentanyl, sufentanil and morphine. The aim of this study is to evaluate the effectiveness of using intraoperative methadone to reduce postoperative pain in patients undergoing kidney transplant surgery (recipients). Patients will be submitted to standardized general anesthesia, and the opioid used in anesthetic induction will be methadone or fentanyl with additional boluses if necessary. After extubation, Fentanyl will be installed in an intravenous analgesia pump controlled by the patient. Differences between groups regarding opioid consumption, pain scores, side effects and patient satisfaction will be assessed

Enrollment

32 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients over 18 years of age
  • With indication for kidney transplant surgery
  • Who sign the informed consent form

Exclusion criteria

  • Patients who refuse to participate in the study
  • Known allergy to any drug used in this protocol
  • Presence of stage III or IV congestive heart failure
  • Increase in QT interval on electrocardiogram (QT> 500 msec)
  • Preemptive kidney transplantation (defined by transplantation in a patient who has not yet started kidney replacement therapy).

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

32 participants in 2 patient groups

Methadone
Experimental group
Description:
Methadone 0,075mg/kg for induction and half of induction dose of boluses as needed during surgery
Treatment:
Drug: Methadone
Fentanyl
Active Comparator group
Description:
Fentanyl 3 mcg/kg for induction and half of induction dose of boluses as needed during surgery
Treatment:
Drug: Fentanyl

Trial contacts and locations

1

Loading...

Central trial contact

Felipe C Machado, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems